BRPI0407742A - uso de glicocorticóides para preparação de formulação utilizáveis no tratamento de angiogênese ocular patológica, bem como formulção assim obtida - Google Patents

uso de glicocorticóides para preparação de formulação utilizáveis no tratamento de angiogênese ocular patológica, bem como formulção assim obtida

Info

Publication number
BRPI0407742A
BRPI0407742A BRPI0407742-3A BRPI0407742A BRPI0407742A BR PI0407742 A BRPI0407742 A BR PI0407742A BR PI0407742 A BRPI0407742 A BR PI0407742A BR PI0407742 A BRPI0407742 A BR PI0407742A
Authority
BR
Brazil
Prior art keywords
formulation
treatment
well
glucocorticoids
ocular angiogenesis
Prior art date
Application number
BRPI0407742-3A
Other languages
English (en)
Inventor
David P Bingaman
Abbot F Clark
Rajni Jani
Stella M Robertson
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BRPI0407742A publication Critical patent/BRPI0407742A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USO DE GLICOCORTICóIDES PARA PREPARAçãO DE FORMULAçõES UTILIZáVEIS NO TRATAMENTO DE ANGIOGêNESE OCULAR PATOLóGICA, BEM COMO FORMULAçãO ASSIM OBTIDA". A presente invenção refere-se a formulações de glicocorticóides sozinhos ou em combinação com acetato de anecortave que são úteis para evitar e tratar angiogênese ocular patológica e edemas associados.
BRPI0407742-3A 2003-02-20 2004-02-05 uso de glicocorticóides para preparação de formulação utilizáveis no tratamento de angiogênese ocular patológica, bem como formulção assim obtida BRPI0407742A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44894403P 2003-02-20 2003-02-20
PCT/US2004/003515 WO2004073608A2 (en) 2003-02-20 2004-02-05 Formulations of glucocorticoids to treat pathologic ocular angiogenesis

Publications (1)

Publication Number Publication Date
BRPI0407742A true BRPI0407742A (pt) 2006-02-14

Family

ID=32908675

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407742-3A BRPI0407742A (pt) 2003-02-20 2004-02-05 uso de glicocorticóides para preparação de formulação utilizáveis no tratamento de angiogênese ocular patológica, bem como formulção assim obtida

Country Status (16)

Country Link
US (2) US20060074061A1 (pt)
EP (1) EP1594511A2 (pt)
JP (2) JP2006518383A (pt)
KR (1) KR20050102653A (pt)
CN (1) CN100431544C (pt)
AR (1) AR043252A1 (pt)
AU (1) AU2004212900A1 (pt)
BR (1) BRPI0407742A (pt)
CA (1) CA2516790A1 (pt)
MX (1) MXPA05008396A (pt)
PL (1) PL378209A1 (pt)
RU (1) RU2005129278A (pt)
TW (1) TW200507858A (pt)
UY (1) UY28203A1 (pt)
WO (1) WO2004073608A2 (pt)
ZA (1) ZA200505990B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006113593A (ru) * 2003-09-23 2006-08-27 Алькон, Инк. (Ch) Препаративные формы триамцинолона ацетонида и анекортава ацетата для инъекций
US7257366B2 (en) * 2003-11-26 2007-08-14 Osmosis Llc System and method for teaching a new language
KR20080059175A (ko) * 2005-09-07 2008-06-26 사우스웨스트 리서치 인스티튜트 방출속도가 향상된 생분해성 미립자 약제학적 제제
US9693967B2 (en) 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
KR20080087814A (ko) * 2005-12-22 2008-10-01 알콘 리서치, 리미티드 보체 인자 ｈ의 위험 변이체가 있는 환자에서 연령 관련황반변성의 예방 및 치료를 위한 ｃ3-전환효소 저해제
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
GB0625844D0 (en) * 2006-12-22 2007-02-07 Daniolabs Ltd The treatment of macular degeneration
MX2009012879A (es) * 2007-07-20 2010-01-14 Alcon Inc Formulacion farmaceutica para suministrar a los ojos compuestos que inhiben el receptor tirosina cinasa (rtki).
CA2796307A1 (en) * 2010-05-10 2011-11-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
WO2015191795A1 (en) * 2014-06-12 2015-12-17 The Research Foundation For The State University Of New York Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
US4686214A (en) * 1985-10-30 1987-08-11 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5556848A (en) * 1993-12-27 1996-09-17 Senju Pharmaceutical Co., Ltd. Ophthalmic suspension containing diflupredonate
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
US5516522A (en) * 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
ES2240180T3 (es) * 1999-10-21 2005-10-16 Alcon Inc. Administracion sub-tenon de medicamentos.
ATE414494T1 (de) * 1999-10-21 2008-12-15 Alcon Inc Medikamentenzuführeinrichtung
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
ES2244361T1 (es) * 2002-08-05 2005-12-16 Alcon, Inc. Uso del acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular asociada a la edad.

Also Published As

Publication number Publication date
KR20050102653A (ko) 2005-10-26
TW200507858A (en) 2005-03-01
ZA200505990B (en) 2006-12-27
US20040167109A1 (en) 2004-08-26
RU2005129278A (ru) 2006-01-27
CA2516790A1 (en) 2004-09-02
JP2007056041A (ja) 2007-03-08
WO2004073608A3 (en) 2005-03-24
PL378209A1 (pl) 2006-03-20
CN100431544C (zh) 2008-11-12
AU2004212900A1 (en) 2004-09-02
MXPA05008396A (es) 2006-03-30
CN1750829A (zh) 2006-03-22
US20060074061A1 (en) 2006-04-06
EP1594511A2 (en) 2005-11-16
WO2004073608A2 (en) 2004-09-02
JP2006518383A (ja) 2006-08-10
UY28203A1 (es) 2004-08-31
AR043252A1 (es) 2005-07-20

Similar Documents

Publication Publication Date Title
DE602005018043D1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
WO2006116591A3 (en) Ophthalmic formulations comprising prednisolone acetate and tobramycin and uses thereof
MX2011013060A (es) Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
MX2009012645A (es) Formulaciones y metodos para tratar el ojo seco.
ECSP034916A (es) Oxazolidinonas substituidas para terapia de combinacion
BRPI0911482A2 (pt) Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer
BR0316203A (pt) Uso de um agente antialérgico e um esteróide para tratar rinite alérgica
WO2006035237A3 (en) Methods and compositions relating to alzheimer's disease
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BRPI0518281A2 (pt) inibidores de 11-beta hidroxilesteràide desidrogenase do tipo i e mÉtodos uso dos mesmos
BR0312232A (pt) Inibidores de caspases e seus usos
BR0311777A (pt) Composição de vesìcula meningocócica multivalente, vacina para o tratamento de doença neisserial, métodos para fabricação de composição de vesìcula meningocócica multivalente e para prevenção ou tratamento de doença neisserial, e, uso de uma quantidade imunologicamente eficaz da vacina
SI1259218T1 (sl) Kozmetični sestavek za tretiranje starajoče se in ali obremenjene kože
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
BR0208533A (pt) Derivados de sapogenina, sìntese e uso dos mesmos e processos com base em seu uso
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
BRPI0407693A (pt) uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos
BR0313546A (pt) Uso de acetato de anacortave para a proteção de acuidade visual em pacientes com degeneração macular relacionada com a idade
CL2008000495A1 (es) Compuestos derivados de tetrahidro-pirazolo[4,3-c]piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como alergias, inflamacion, dolor, cancer, entreotras.
WO2002067971A3 (en) Use of endostatin in the treatment of ocular neovascularization
BR0311866A (pt) Composições de saponinas ou sapogeninas para terapia de câncer

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.